Actitan F
ApprovedSmall molecule
Actitan F is one of 14 small molecule programs targeting Acute Diarrhea. It is currently in Approved.
1
Indications
1
Total Trials
0
Active Trials
13
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
16 competitors in Acute Diarrhea
#DrugCompanyPhaseTrials
1Xifaxan
SSalix
Approved
Azulfidine
PfizerPhase 3
Bacillus Clausii
SanofiApproved
Galzin
AAmerican Regent, Inc.
Phase 3
Oral Anti-Diabetic Drugs
SanofiApproved
Zinc Sulphate
IInternational Centre for Diarrhoeal Disease Research, Bangladesh
Phase 3
Actitan F
FFederico II University
Approved
Standard DAPT Duration
FFederico II University
Approved
Loperamide Hydrochloride
Johnson & JohnsonPhase 3
Racecadotril
MMcNeil AB
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Actitan F. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- FFederico II University